IRANIAN JOURNAL OF BASIC MEDICAL SCIENCES, vol.18, no.11, pp.1093-1099, 2015 (SCI-Expanded)
Objective(s): Increasing cytokines and reactive oxygen species (ROS) during ischemia reperfusion (I-R) leads to the lung damage. Adalimumab (Ada) is a potent tumor necrosis factor-alpha (TNF-alpha) inhibitor agent. We aimed to evaluate whether Ada would prevent the lung tissue from damage development over the I-R process.